SCHEMBL472937

SCHEMBL472937

NCCC[C@@H](NO)C(=O)O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FOLH1 Q04609 2/20 0.50
CPB2 Q96IY4 3/20 0.47
GSR P00390 1/20 0.45
RNPEP Q9H4A4 1/20 0.43
SLC6A5 Q9Y345 1/20 0.42
GNPAT O15228 1/20 0.42
MMP2 P08253 1/20 0.41
MMP9 P14780 1/20 0.41
GGT1 P19440 1/20 0.40
GABRR1 P24046 3/20 0.38
GABRR3 A8MPY1 1/20 0.37
GABRP O00591 1/20 0.37
GABRD O14764 1/20 0.37
HDAC3 O15379 1/20 0.37
GABBR2 O75899 1/20 0.37
LMNA P02545 1/20 0.37
CYP1A2 P05177 1/20 0.37
THRB P10828 1/20 0.37
GABRA1 P14867 1/20 0.37
TSHR P16473 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL472934 1.00 FOLH1 (0.50) FOLH1CPB2GSRRNPEPSLC6A5
SCHEMBL472935 1.00 FOLH1 (0.50) FOLH1CPB2GSRRNPEPSLC6A5
SCHEMBL1054672 0.93 FOLH1 (0.58) FOLH1CPB2GSRRNPEPSLC6A5
SCHEMBL48407 0.93 FOLH1 (0.58) FOLH1CPB2GSRRNPEPSLC6A5
SCHEMBL48406 0.93 FOLH1 (0.58) FOLH1CPB2GSRRNPEPSLC6A5
Ammonia Solution, Strong SCHEMBL6151757 0.91 FOLH1 (0.56) FOLH1CPB2GSRRNPEPSLC6A5
Hydrochloric Acid SCHEMBL4067567 0.91 FOLH1 (0.56) FOLH1CPB2GSRRNPEPSLC6A5
Hydrochloric Acid SCHEMBL16732003 0.91 FOLH1 (0.56) FOLH1CPB2GSRRNPEPSLC6A5
Methane SCHEMBL28201404 0.91 FOLH1 (0.56) FOLH1CPB2GSRRNPEPSLC6A5
Hydrochloric Acid SCHEMBL4067569 0.91 FOLH1 (0.56) FOLH1CPB2GSRRNPEPSLC6A5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3265130-B1 ANTIBACTERIAL SIDEROMYCINS HSIRI THERAPEUTICS LLC (US) 2024-05-22 EP disclosed
US-11779634-B2 Fungal iron acquisition inhibitors and uses thereof CASE WESTERN RESERVE UNIVERSITY (US) 2023-10-10 US disclosed
US-20220211820-A1 FUNGAL IRON ACQUISITION INHIBITORS AND USES THEREOF UNIV CASE WESTERN RESERVE (US) 2022-07-07 US disclosed
US-11229685-B2 Fungal iron acquisition inhibitors and uses thereof CASE WESTERN RESERVE UNIVERSITY (US) 2022-01-25 US disclosed
US-10548860-B2 HIF-1 modulator paint formulation and uses thereof THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2020-02-04 US disclosed
US-20190192452-A1 HIF-1 MODULATOR PAINT FORMULATION AND USES THEREOF THE JOHNS HOPKINS UNIVERSITY 2019-06-27 US disclosed
US-10220009-B2 HIF-1 modulator paint formulation and uses thereof THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2019-03-05 US disclosed
EP-2970150-B1 FORMATION OF N-PROTECTED BIS-3,6-(4-AMINOBUTYL)-2,5-DIKETOPIPERAZINE THROUGH A CYCLIC ALPHA-N-PROTECTED AMINO ESTER MANNKIND CORP (US) 2018-09-19 EP disclosed
US-9763899-B2 Iron chelators and use thereof for reducing transplant failure during rejection episodes THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2017-09-19 US disclosed
US-20170252310-A9 Iron Chelators and Use Thereof for Reducing Transplant Failure During Rejection Episodes NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2017-09-07 US disclosed
WO-1999022593-A1 USE OF EXOCHELINS IN THE PRESERVATION OF ORGANS FOR TRANSPLANT THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1999-05-14 WO disclosed
WO-1998058635-A2 METHOD FOR THE TREATMENT OF CANCER WITH EXOCHELINS OF MYCOBACTERIUM TUBERCULOSIS KEYSTONE BIOMEDICAL INC. (US) 1998-12-30 WO disclosed
WO-1998034619-A1 METHOD FOR THE TREATMENT OF ATHEROSCLEROSIS AND VASCULAR INJURY BY PREVENTION OF VASCULAR SMOOTH MUSCLE CELL PROLIFERATION KEYSTONE BIOMEDICAL, INC. (US) 1998-08-13 WO disclosed
CN-1145588-A Novel iron chelator and inhibitor of iron-mediated oxidation UNIV CALIFORNIA (US) 1997-03-19 CN disclosed
EP-0754044-A1 NOVEL IRON CHELATOR AND INHIBITOR OF IRON-MEDIATED OXIDATION THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1997-01-22 EP disclosed
WO-1996023502-A1 NOVEL IRON CHELATOR AS INHIBITOR OF IRON-MEDIATED OXIDATION THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1996-08-08 WO disclosed
US-4766110-A INHIBITS ANGIOTENSIN CONVERTING ENZYME, HYPOTENSIVE AGENTS RYAN JAMES W (US) 1988-08-23 US disclosed
EP-0073143-B1 NOVEL COMPLEX AMIDO AND IMIDO DERIVATIVES OF CARBOXYALKYL PEPTIDES AND THIOETHERS AND ETHERS OF PEPTIDES Ryan, James Walter (US) 1985-11-21 EP disclosed
EP-0073143-A2 Novel complex amido and imido derivatives of carboxyalkyl peptides and thioethers and ethers of peptides Ryan, James Walter (US) 1983-03-02 EP disclosed
EP-0048159-A2 Novel carboxyalkyl peptides and thioethers and ethers of peptides as antihypertensive agents UNIVERSITY OF MIAMI (US) 1982-03-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11229685-B2 Fungal iron acquisition inhibitors and uses thereof SLC40A1, SLC30A6, SLC30A7 FOLH1 190/4885CPB2 1262/4885GSR 578/4885
US-20220211820-A1 FUNGAL IRON ACQUISITION INHIBITORS AND USES THEREOF SLC40A1, SLC30A6, SLC30A7 FOLH1 190/4885CPB2 1262/4885GSR 578/4885
US-11779634-B2 Fungal iron acquisition inhibitors and uses thereof SLC40A1, SLC30A6, SLC30A7 FOLH1 190/4885CPB2 1262/4885GSR 578/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.